Zinzani Pier Luigi, Broccoli Alessandro
Institute of Haematology "L. e A. Seràgnoli", Via Massarenti, 9, 40138 Bologna, Italy.
Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):149-157. doi: 10.1016/j.beha.2016.07.003. Epub 2016 Nov 4.
Efficacy, safety and mechanisms of action of novel agents in marginal zone lymphoma patients, both with a nodal and extranodal presentation, are reviewed. Data on lenalidomide, bortezomib and yttrium-ibrutumomab tiuxetan are obtained from trials specifically designed for patients affected by marginal zone lymphoma and with various disease presentations. The role of targeted agents, such as obinutuzumab, ibrutinib and idelalisib, and of some very new drugs (venetoclax, copanlisib, ublituximab and TGR-1202) is also discussed, taking into account the most relevant experiences in patients with indolent non-Hodgkin's lymphomas. A glance to some possible drug combinations will also be provided, along with an update of the most relevant ongoing trials.
本文综述了新型药物在边缘区淋巴瘤患者（包括淋巴结和结外表现）中的疗效、安全性及作用机制。关于来那度胺、硼替佐米和钇-伊布替尼的相关数据来自专门针对边缘区淋巴瘤患者且具有不同疾病表现的试验。同时，考虑到惰性非霍奇金淋巴瘤患者的相关经验，还讨论了靶向药物（如奥妥珠单抗、伊布替尼和艾代拉里斯）以及一些非常新的药物（维奈托克、库潘尼西、ublituximab和TGR-1202）的作用。本文还将简要介绍一些可能的药物联合方案，以及最新的相关正在进行的试验情况。
